Controlled Organization of Inorganic Materials Using Biological Molecules for Activating Therapeutic Functionalities

Morgan Chandler; Brian Minevich; Brandon Roark; Mathias Viard; M. Brittany Johnson; Mehedi H. Rizvi; Thomas A. Deaton; Seraphim Kozlov; Martin Panigaj; Joseph B. Tracy; Yaroslava G. Yingling; Oleg Gang; Kirill A. Afonin

doi:10.1021/acsami.1c09230

journal article·2021-08-25Open access

Controlled Organization of Inorganic Materials Using Biological Molecules for Activating Therapeutic Functionalities

Morgan Chandler, Brian Minevich, Brandon Roark, Mathias Viard, M. Brittany Johnson, Mehedi H. Rizvi, Thomas A. Deaton, Seraphim Kozlov, Martin Panigaj, Joseph B. Tracy, Yaroslava G. Yingling, Oleg Gang, Kirill A. Afonin

ACS Applied Materials & Interfaces· Volume 13· Issue 33

Publisher page Open full text

Source abstract

Abstract

Precise control over the assembly of biocompatible three-dimensional (3D) nanostructures would allow for programmed interactions within the cellular environment. Nucleic acids can be used as programmable crosslinkers to direct the assembly of quantum dots (QDs) and tuned to demonstrate different interparticle binding strategies. Morphologies of self-assembled QDs are evaluated via gel electrophoresis, transmission electron microscopy, small-angle X-ray scattering, and dissipative particle dynamics simulations, with all results being in good agreement. The controlled assembly of 3D QD organizations is demonstrated in cells via the colocalized emission of multiple assembled QDs, and their immunorecognition is assessed via enzyme-linked immunosorbent assays. RNA interference inducers are also embedded into the interparticle binding strategy to be released in human cells only upon QD assembly, which is demonstrated by specific gene silencing. The programmability and intracellular activity of QD assemblies offer a strategy for nucleic acids to imbue the structure and therapeutic function into the formation of complex networks of nanostructures, while the photoluminescent properties of the material allow for optical tracking in cells in vitro.

Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials Biomaterials

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Quantum Dots Synthesis And Properties · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States

Department of Chemical Engineering, Columbia University, New York, New York 10027, United States

Laboratory of Integrative Cancer Immunology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, Maryland 21702, United States

Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States

Department of Materials Science and Engineering, North Carolina State University, Raleigh, North Carolina 27695, United States

Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Safarik University in Kosice, Kosice 04154, Slovak Republic

Department of Applied Physics and Applied Mathematics, Columbia University, New York, New York 10027, United States

Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York 11973, USA

Funding

European Commission · Frederick National Laboratory for Cancer Research · University of North Carolina · National Science Foundation · U.S. Department of Health and Human Services

References (63)

Show source-provided references

1. 10.1021/acsanm.0c0135810.1021/acsanm.0c01358 ↗

2. 10.1021/am303189h10.1021/am303189h ↗

3. 10.1016/j.biomaterials.2014.05.07110.1016/j.biomaterials.2014.05.071 ↗

4. 10.1016/j.nano.2020.10221710.1016/j.nano.2020.102217 ↗

5. 10.1002/anie.20046090510.1002/anie.200460905 ↗

6. 10.1021/nl049571610.1021/nl0495716 ↗

7. 10.1021/nl034004o10.1021/nl034004o ↗

8. 10.1016/j.copbio.2019.12.02510.1016/j.copbio.2019.12.025 ↗

9. 10.1038/nature0656010.1038/nature06560 ↗

10. 10.1038/nature0650810.1038/nature06508 ↗

11. 10.1038/s41586-020-2718-610.1038/s41586-020-2718-6 ↗

12. 10.1038/s41578-019-0087-210.1038/s41578-019-0087-2 ↗

13. 10.1021/nl502385k10.1021/nl502385k ↗

14. 10.1021/nl051264s10.1021/nl051264s ↗

15. 10.3390/nano812098410.3390/nano8120984 ↗

16. 10.1021/acsnano.9b0652210.1021/acsnano.9b06522 ↗

17. 10.1016/j.addr.2021.04.01110.1016/j.addr.2021.04.011 ↗

18. 10.1016/j.addr.2021.11383510.1016/j.addr.2021.113835 ↗

19. 10.1016/j.nano.2020.10228510.1016/j.nano.2020.102285 ↗

20. 10.1021/acs.nanolett.5b0465110.1021/acs.nanolett.5b04651 ↗

21. Zakrevsky P. · 2017 · 30310.1007/978-1-4939-7138-1_20 ↗

22. 10.1016/j.aca.2004.03.08010.1016/j.aca.2004.03.080 ↗

23. 10.1002/anie.20050126210.1002/anie.200501262 ↗

24. 10.1021/ar400316h10.1021/ar400316h ↗

25. 10.1038/3502052410.1038/35020524 ↗

26. 10.1038/nnano.2009.8310.1038/nnano.2009.83 ↗

27. 10.1002/anie.20090708210.1002/anie.200907082 ↗

28. 10.1093/nar/gkx00810.1093/nar/gkx008 ↗

29. 10.1093/nar/gky121510.1093/nar/gky1215 ↗

30. 10.1021/acs.accounts.6b0054210.1021/acs.accounts.6b00542 ↗

31. 10.1021/acsnano.9b0129410.1021/acsnano.9b01294 ↗

32. 10.1021/ja209351u10.1021/ja209351u ↗

33. 10.1021/la400018610.1021/la4000186 ↗

34. 10.2147/ijn.s13862410.2147/ijn.s138624 ↗

35. 10.1038/nnano.2011.10010.1038/nnano.2011.100 ↗

36. 10.1021/ja111542t10.1021/ja111542t ↗

37. 10.1039/c7tb01425b10.1039/c7tb01425b ↗

38. 10.1002/anie.20080016910.1002/anie.200800169 ↗

39. 10.1126/science.110427410.1126/science.1104274 ↗

40. 10.1038/mtna.2015.2510.1038/mtna.2015.25 ↗

41. 10.3390/s1708173610.3390/s17081736 ↗

42. 10.1038/nnano.2016.14010.1038/nnano.2016.140 ↗

43. 10.1021/acssensors.6b0035210.1021/acssensors.6b00352 ↗

44. 10.1038/nchem.95710.1038/nchem.957 ↗

45. 10.1038/nnano.2013.4410.1038/nnano.2013.44 ↗

46. 10.1126/science.120052010.1126/science.1200520 ↗

47. 10.1093/nar/gkt100110.1093/nar/gkt1001 ↗

48. 10.1021/acs.nanolett.5b0467610.1021/acs.nanolett.5b04676 ↗

49. 10.1209/0295-5075/30/4/00110.1209/0295-5075/30/4/001 ↗

50. 10.1016/s1359-0294(98)80089-710.1016/s1359-0294(98)80089-7 ↗

51. Deaton T. A. · 2021 · 7510.1007/978-981-33-6639-8_4 ↗

52. 10.1039/c5sm01742d10.1039/c5sm01742d ↗

53. 10.1016/j.cbpa.2015.06.00210.1016/j.cbpa.2015.06.002 ↗

54. 10.1016/j.cpc.2012.03.00510.1016/j.cpc.2012.03.005 ↗

55. 10.1006/jcph.1995.103910.1006/jcph.1995.1039 ↗

56. 10.1002/marc.20170042210.1002/marc.201700422 ↗

57. 10.1021/acsami.6b0559610.1021/acsami.6b05596 ↗

58. 10.1002/mats.20140004310.1002/mats.201400043 ↗

59. 10.3389/fncel.2018.0045810.3389/fncel.2018.00458 ↗

60. 10.4049/jimmunol.180.12.824110.4049/jimmunol.180.12.8241 ↗

61. 10.1038/nprot.2011.41810.1038/nprot.2011.418 ↗

62. 10.1038/nmeth.208910.1038/nmeth.2089 ↗

63. 10.5334/jors.bn10.5334/jors.bn ↗